Series date: 
01/01/2024 - 12:00pm CST to 12/31/2024 - 11:59pm CST

OBJECTIVES: Upon completion of this activity, the participant should be able to:
1. Apply NCCN guidelines when treating cancer patients.
2. Identify evidence-based timing of surgical intervention amongst the metastatic patient population
3. Continuously introduce new treatment modalities as appropriate
4. Contribute to and help formulate the best treatment plan for patient's cases discussed

PLANNER/MODERATOR DISCLOSURE: The planners have no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information, please contact Coral.Fraire@BSWHealth.org 

 

Series location: 
Baylor Scott & White Medical Center - Temple
2401 S 31st Street
Temple, TX 76508
United States
See map: Google Maps

Sessions

Session Date
20240104 Temple Pathology JC - The use of diagnostic patterns for interventional cytopathology during rapid on-site evaluation and final classification 01/04/2024 - 12:00pm to 1:00pm CST
20240201 Temple Pathology JC -Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis 02/01/2024 - 12:00pm to 1:00pm CST
20240314 Temple Pathology JC -Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions 03/14/2024 - 12:00pm to 1:00pm CDT
20240404 Temple Pathology JC -The Impact of the 2022 WHO Classification of Thyroid Neoplasms on Everyday Practice of Cytopathology and A reappraisal of the epidemiology of Spitz neoplasms in the molecular era: A retrospective cohort study 04/04/2024 - 12:00pm to 1:00pm CDT
20240502 Temple Pathology JC -Melanocytic naevi, melanocytomas and emerging concepts 05/02/2024 - 12:00pm to 1:00pm CDT
20240606 Temple Pathology JC - Cell Stem Cell: Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma 06/06/2024 - 12:00pm to 1:00pm CDT
20240711 Temple Pathology JC -A review and analysis of outcomes in randomized clinical trials of plasma transfusion in patients with bleeding or for the prevention of bleeding: The BEST collaborative study 07/11/2024 - 12:00pm to 1:00pm CDT
20240801 Temple Pathology JC - Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists 08/01/2024 - 12:00pm to 1:00pm CDT
20240905 Temple Pathology JC -Prevalence and interpretation of AFF immunostain of DEK::AFF2 fusion‑associated papillary squamous cell carcinoma in a retrospective cohort of recurrent sinonasal papillomas 09/05/2024 - 12:00pm to 1:00pm CDT
20241003 Temple Pathology JC -Papillary Renal Cell Carcinoma: Evolving Classification by Combined Morphologic and Molecular Means 10/03/2024 - 12:00pm to 1:00pm CDT

Pages